Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report)’s share price was down 7.1% on Thursday. The company traded as low as $13.05 and last traded at $13.3120. Approximately 544,883 shares were traded during trading, a decline of 54% from the average daily volume of 1,172,508 shares. The stock had previously closed at $14.33.
Wall Street Analyst Weigh In
A number of research firms have commented on BBNX. Robert W. Baird boosted their target price on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. Barclays assumed coverage on Beta Bionics in a research report on Tuesday, October 6th. They set an “overweight” rating and a $30.00 price target for the company. Truist Financial upped their target price on Beta Bionics from $23.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, September 24th. William Blair began coverage on Beta Bionics in a research note on Friday, August 21st. They set a “market perform” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and an average target price of $23.69.
Check Out Our Latest Analysis on BBNX
Beta Bionics Trading Down 7.0%
The company has a market cap of $724.44 million, a price-to-earnings ratio of -7.22 and a beta of 3.44. The business has a fifty day moving average price of $18.23 and a two-hundred day moving average price of $14.87.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.01. The firm had revenue of $35.51 million during the quarter. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. On average, analysts anticipate that Beta Bionics, Inc. will post -2.04 EPS for the current year.
Insider Transactions at Beta Bionics
In other Beta Bionics news, Director Christy Jones sold 6,430 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total value of $147,890.00. Following the completion of the sale, the director owned 19,564 shares in the company, valued at approximately $449,972. This trade represents a 24.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mike Mensinger sold 4,375 shares of Beta Bionics stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25. Following the sale, the insider directly owned 180,040 shares of the company’s stock, valued at $3,440,564.40. This represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 103,844 shares of company stock worth $2,026,928. 5.30% of the stock is owned by company insiders.
Hedge Funds Weigh In On Beta Bionics
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Beta Bionics during the second quarter valued at about $52,340,000. Eversept Partners LP grew its stake in shares of Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after acquiring an additional 736,576 shares during the period. Bruce & Co. Inc. purchased a new stake in shares of Beta Bionics during the 1st quarter valued at approximately $5,518,000. Bank of America Corp DE bought a new stake in shares of Beta Bionics during the 2nd quarter valued at $8,566,000. Finally, Perceptive Advisors LLC increased its holdings in shares of Beta Bionics by 39.8% in the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares during the period.
About Beta Bionics
Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.
Read More
- Five stocks we like better than Beta Bionics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
